• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CareDx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/12/25 4:32:37 PM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email
    8-K
    false 0001217234 0001217234 2025-06-12 2025-06-12
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): June 12, 2025

     

     

    CAREDX, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-36536   94-3316839

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    8000 Marina Boulevard, 4th Floor
    Brisbane, California 94005
    (Address of Principal Executive Offices) (Zip Code)

    (415) 287-2300

    Registrant’s telephone number, including area code

    N/A

    (Former Name, or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Exchange Act:

     

    (Title of each class)

     

    (Trading
    Symbol)

     

    (Name of exchange

    on which registered)

    Common Stock, $0.001 Par Value   CDNA   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On June 12, 2025, CareDx, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company approved an amendment (the “Plan Amendment”) to the Company’s 2024 Equity Incentive Plan (the “Plan”) in accordance with the voting results set forth below under Item 5.07. The Plan Amendment was previously adopted by the Company’s Board of Directors at its meeting on April 23, 2025, subject to and effective upon stockholder approval.

    The material terms of the Plan Amendment were described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2025 (the “Proxy Statement”) under the caption “Proposal No. 4 Approval of Amendment to the 2024 Equity Incentive Plan.” The Plan Amendment authorizes an increase in the available shares reserved under the Plan by 1,600,000 shares, or approximately 3% of common shares issued and outstanding, subject to adjustment as provided in the Plan, and an equivalent increase in the number of shares of stock available for grant pursuant to incentive stock options, as more fully described in the Proxy Statement.

    The above description of the Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Plan Amendment, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On June 12, 2025, the Company held the Annual Meeting. Of the 55,596,737 shares of the Company’s common stock outstanding as of April 15, 2025, the record date for the Annual Meeting, 49,757,768 shares were represented at the Annual Meeting virtually or by proxy, constituting approximately 89.49% of the outstanding shares entitled to vote and constituting a quorum for the transaction of business.

    At the Annual Meeting, the Company’s stockholders considered four proposals, each of which is described in more detail in the Proxy Statement.

    Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal.

    Proposal No. 1 - To elect two Class II directors to serve until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified.

     

    Nominee  

    Votes For

     

    Votes Withheld

     

    Broker Non-Votes

    Fred E. Cohen, M.D., D. Phil

     

    42,173,236

     

    1,558,136

     

    6,026,396

    R. Bryan Riggsbee

     

    42,839,955

     

    891,417

     

    6,026,396

    As a result, the Company’s stockholders voted to elect each of Fred E. Cohen, M.D., D. Phil and R. Bryan Riggsbee as Class II directors to serve until the Company’s 2026 annual meeting of stockholders or until his respective successor is duly elected and qualified.

    Proposal No. 2 - To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2025.

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non-Votes

    49,638,906

      95,842  

    23,020

     

    0

    As a result, the Company’s stockholders voted to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2025.

    Proposal No. 3 - To approve, on an advisory basis, the compensation of the Company’s named executive officers.

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non-Votes

    40,012,994

     

    3,694,527

     

    23,851

     

    6,026,396

    As a result, the Company’s stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers.

     


    Proposal No. 4 - To approve the Amendment to the Company’s 2024 Equity Incentive Plan.

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non-Votes

    27,296,700

     

    16,389,509

     

    45,163

     

    6,026,396

    As a result, the Company’s stockholders voted to approve the Plan Amendment.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    No.
       Description
    10.1    Amendment No. 1 to the CareDx, Inc. 2024 Equity Incentive Plan.
    104    Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 12, 2025   CAREDX, INC.
        By:  

    /s/ John Hanna

          John Hanna
          President and Chief Executive Officer
    Get the next $CDNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    8/15/2023$12.00Mkt Perform → Outperform
    Raymond James
    5/11/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $CDNA
    SEC Filings

    See more
    • CareDx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CareDx, Inc. (0001217234) (Filer)

      6/12/25 4:32:37 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by CareDx Inc.

      144 - CareDx, Inc. (0001217234) (Subject)

      6/11/25 4:20:36 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - CareDx, Inc. (0001217234) (Filer)

      6/3/25 4:30:13 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CareDx Announces Repurchase of 5% of Outstanding Shares

      Board of Directors Authorizes New $50 Million Share Repurchase Program CareDx, Inc. (NASDAQ:CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock representing approximately 5% of outstanding shares. The share repurchase follows the completion of the company's seventh consecutive quarter of testing services volume growth and a first-quarter total revenue of $84.7 million, representing 18% year-over-year growth. CareDx ended

      6/3/25 4:30:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports First Quarter 2025 Results

      First Quarter Revenue of $84.7 Million, Increased 18% Year-Over-Year Grew Testing Services Volume to Approximately 47,100, Marking Seventh Consecutive Quarter of Sequential Testing Services Volume Growth CareDx, Inc. (NASDAQ:CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of $84.7 million, increased 18% year-over-year Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100, increased 12% year-over-year GAAP net loss of $10.4 million, non-GAAP net income of $5.4 million, and positive adjusted EBITDA of $4.6 million,

      4/30/25 4:05:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ ("CareDx" or the "Company")— a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 7, 2025, CareDx granted to Jennifer Foley, the Company's newly appointed Chief Product Officer, certain stock awards as an inducement material to Ms. Foley's employment with CareDx. CareDx granted Ms. Foley 36,231 restricted stock units ("RSUs") pursuant to the Company's 2016 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Company's Board o

      4/21/25 4:01:00 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CareDx upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously

      1/15/25 7:29:19 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • Wells Fargo initiated coverage on CareDx with a new price target

      Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00

      8/28/24 7:38:28 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx upgraded by BTIG Research with a new price target

      BTIG Research upgraded CareDx from Neutral to Buy and set a new price target of $40.00

      8/19/24 8:49:21 AM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Maag Peter sold $192,420 worth of shares (10,000 units at $19.24), decreasing direct ownership by 3% to 318,846 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      6/20/25 4:30:13 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Director Goldberg Michael was granted 12,103 shares, increasing direct ownership by 9% to 152,998 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      6/17/25 4:56:07 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Director Cohen Fred E was granted 12,103 shares, increasing direct ownership by 8% to 155,265 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      6/17/25 4:35:09 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Leadership Updates

    Live Leadership Updates

    See more
    • CareDx Appoints Jing Huang Chief Data and AI Officer

      CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Company's long-term strategic growth plan. CareDx intends to share its long-term growth strategy during an Investor Day on October 15, 2024. Huang is a recognized leader in data science and machine learning, bringing to CareDx a proven trac

      10/9/24 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer

      CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith Kennedy brings more than 20 years of experience and e

      9/12/24 7:01:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Appoints John W. Hanna as its New President and Chief Executive Officer

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. "John is an outstanding leader with a proven track record of building high-performing teams that deliver consistent results. With extensive experience in the molecular diagnostics and life sciences tools industries, John is the right executive to bring strategic leadership to CareDx to propel the compan

      4/16/24 4:02:00 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/14/24 5:13:57 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/8/24 2:34:10 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/5/24 6:07:26 AM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Financials

    Live finance-specific insights

    See more
    • CareDx to Report First Quarter 2025 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please

      4/8/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx to Report Fourth Quarter and Full Year 2024 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to

      2/11/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports Preliminary Financial Results for Third Quarter 2024

      Third Quarter 2024 Financial Results to be Reported on November 4, 2024 CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, an increase of approximately 23% year-over-year. Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year. Testi

      10/15/24 6:00:00 AM ET
      $CDNA
      Medical Specialities
      Health Care